Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

An intact skin barrier is crucial to prevent infection in cases of tether-induced tenosynovitis.

This study found that tofacitinib may be effective in treating various pediatric rheumatic diseases, particularly juvenile idiopathic arthritis, although some patients did not respond, and side effects were observed.

This study found that the meropenem-loaded spanlastic formulation showed strong potential as an effective topical therapy for bacterial skin infections in non-diabetic mice, demonstrating superior therapeutic activity and wound healing compared to free meropenem.

In this study, the researchers shared their experiences with using local intracanal antibiotic therapy for treating endodontic bacterial infections, noting that current disinfectants, though effective, are highly toxic to human cells.

This study found that RADA-PRG hydrogels enhanced skin-derived precursor cell proliferation and improved hair follicle neogenesis in mice, suggesting potential use as a scaffold material in tissue engineering.

This study analyzed post-marketing data from the U.S. FDA Adverse Event Reporting System and identified both known and new safety concerns for Avacopan, an anti-neutrophil cytoplasmic antibodies-associated vasculitis treatment, emphasizing the need for monitoring during early treatment stages.

This study found that cefazolin-loaded silica nanoparticles embedded in polycaprolactone nanofibers successfully inhibited Staphylococcus aureus growth while maintaining stem cell viability, suggesting their potential use in wound healing.

This study found that tofacitinib and baricitinib, when administered with unorthodox weight-stratified dosing in pediatric patients with moderate-to-severe AA, showed comparable efficacy and tolerability, though baricitinib's efficacy decreased with non-standard dosing.

This study found that platelet-rich plasma can transiently inhibit bacterial growth in vitro against multidrug-resistant strains from diabetic foot infections, although its efficacy diminished over time and did not affect biofilm formation.

This review discusses the use of tofacitinib as a treatment for plaque psoriasis, highlighting its efficacy and safety in clinical trials, but notes unresolved questions regarding long-term safety.

This study found that tofacitinib may be effective for treating pediatric rheumatic diseases, with especially promising results in patients with autoinflammatory diseases, arthritis and alopecia, and juvenile dermatomyositis.

In this case report, a female patient with Graham-Little-Piccardi-Lassueur Syndrome and hidradenitis suppurativa showed significant improvement in symptoms, including hair loss and lesions, after six months of treatment with tofacitinib, with no recurrence or adverse effects over a two-year follow-up.

In this study, pediatric patients with alopecia areata treated with systemic tofacitinib showed significant improvement at 12 months, but the small sample size and retrospective design limit conclusions about its effectiveness.

This study found that the new cocrystal formulation KET-PABA improved the antimycotic efficiency of ketoconazole and induced an anti-inflammatory response without causing skin sensitization in mice.

Tofacitinib might be used to treat hair loss.

In this report, a female patient with ulcerative colitis, alopecia areata, and pyoderma gangrenosum showed improvement in all three conditions after being treated with tofacitinib.

This study demonstrated that a new topical treatment using ketotifen-loaded microneedles, designed for prolonged release, significantly reduced inflammatory markers in an animal model of allergic conjunctivitis, suggesting enhanced therapeutic delivery and sustained ocular benefits.

Topical tofacitinib helped a man with severe scalp condition after other treatments failed.

In this study, oral tofacitinib significantly reduced alopecia severity in pediatric patients with moderate-to-severe alopecia areata over 24 weeks, with 42.2% achieving complete or near-complete hair regrowth, although further research is needed on long-term safety and relapse rates.

This study found that in treating mild to moderate acne vulgaris, topical tazarotene 0.1% was more effective than topical adapalene 0.1%, with 100% of patients using tazarotene achieving the desired outcome compared to 75.3% in the adapalene group.

This report describes a case in which poststreptococcal reactive arthritis in a girl was effectively treated with naproxen, and highlights the importance of considering nongroup A Streptococcus in similar presentations.

This study found that tofacitinib and baricitinib had an acceptable adverse reaction profile when used to treat rheumatoid arthritis, with similar side effects to those described in their technical data sheets.

In this study, topical application of piperonylic acid was observed to accelerate wound healing in mice by enhancing EGFR activation, keratinocyte modulation, and collagen deposition, suggesting its potential as a treatment for skin injuries.

This study found that treating paracoccidioidomycosis-infected mice with a nanoparticle formulation of itraconazole led to higher drug accumulation in lung, liver, and spleen tissues, improved treatment efficacy, and reduced side effects compared to traditional oral solutions.

This study found that oral paclitaxel combined with encequidar improved tumor response rates compared to intravenous paclitaxel in women with metastatic breast cancer, while also reducing neuropathy but increasing certain gastrointestinal and neutropenic side effects.

In this study, researchers at Nottingham Children's Renal Unit found that most pediatric patients switching from Prograf to the generic tacrolimus preparation Adoport maintained stable tacrolimus levels and therapeutic effectiveness, supporting Adoport's use as a cost-saving alternative for the NHS.

This case report observed hair regrowth following the treatment of alopecia universalis and atopic dermatitis with tofacitinib, a JAK inhibitor.

This study suggests that itraconazole may significantly improve therapy for aspergillosis, with 12 out of 15 evaluable patients responding to the treatment.